Edgewise Therapeutics Reports Positive Results on Sevasemten Program

Edgewise Therapeutics, which received early funding from CureDuchenne, has reported positive results in its sevasemten program for Becker and Duchenne muscular dystrophies. New open-label data in Becker from the MESA trial demonstrated sustained disease stabilization up to three years in participants, reinforcing prior clinical findings from the ARCH and CANYON trials. Edgewise also reported encouraging topline data from the Phase 2 trials in Duchenne, and plan to meet with the FDA later this year to discuss the pivotal Phase 3 trial. 

Link to press release: https://investors.edgewisetx.com/news/news-details/2025/Edgewise-Therapeutics-Reports-Positive-Results-on-Sevasemten-Program-for-Becker-and-Duchenne-Muscular-Dystrophies/default.aspx